Concurrent TERT alterations were only identified in EGRF‐LFD carriers with glioblastoma and melanoma while concurrent TP53 alterations were only identified in EGRF‐LFD carriers with lung cancer and colorectal cancer. This evidence concerns the gene TP53 and melanoma.